Table 2.
Baseline characteristics.
| Characteristic | Enoxaparin (n = 114) | Rivaroxaban (n = 114) | Total (n = 228) | P-value |
|---|---|---|---|---|
| Age, median (range), y | 56 (20-82) | 54 (23-87) | 55 (20-87) | 0.2864 |
| Body mass index, median (range) | 28.1 (15.5-46.8) | 28.5 (14.7-48.0) | 28.3 (14.7-48.0) | 0.6033 |
| Caprini score | N (%) | N (%) | ||
| <5 | 60 (53) | 68 (60) | 128 (56) | 0.3502 |
| ≥5 | 54 (47) | 46 (40) | 100 (44) | |
| Suspected cancer site | ||||
| Cervical | 49 (43) | 47 (41) | 96 (42) | 0.4638 |
| Uterine | 31 (27) | 39 (34) | 70 (31) | |
| Ovarian | 34 (30) | 28 (25) | 62 (27) | |
| Surgical intervention | ||||
| Open | 110 (96) | 114 (100) | 224 (98) | 0.1217 |
| Minimally invasive | 1 (1) | 0 (0) | 1 (0) | |
| Other | 3 (3) | 0 (0) | 3 (2) | |
| Duration of surgery, median (range), min | 140.1 (40-355) | 142.9 (40-360) | 141.5 (40-360) | 0.7507 |
| Duration of hospitalization, days | 4.1 (1-38) | 3.3 (1-10) | 3.7 (1-38) | 0.5681 |
| Confirmed diagnosis by anatomopathological exam | ||||
| Malignant or borderline | 112 (49) | 109 (48) | 221 (97) | 0.4458 |
| Benign | 2 (1) | 5 (2) | 7 (3) | |
| Stage of malignant tumor | n = 112 | n = 109 | n = 221 | |
| In Situ | ||||
| Uterine | 8 (7) | 12 (11) | 20 (9) | 0.7111 |
| Cervical | 0 (0) | 0 (0) | 0 (0) | |
| Ovarian | 2 (2) | 2 (2) | 4 (2) | |
| Low (I or II) | ||||
| Uterine | 19 (17) | 24 (22) | 43 (19) | 0.8611 |
| Cervical | 36 (32) | 37 (34) | 73 (33) | |
| Ovarian | 12 (11) | 14 (13) | 26 (12) | |
| High (III or IV) | ||||
| Uterine | 4 (3) | 1 (1) | 5 (2) | 0.6818 |
| Cervical | 13 (12) | 7 (6) | 20 (9) | |
| Ovarian | 18 (16) | 12 (11) | 30 (14) |